VANI Vivani Medical, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1266806 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-3.9%
TTM EPS YoY26.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-372.2%
ROA-89.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | — | — | $260,000 |
| Cost of revenue | — | — | — | — | $130,000 |
| Gross profit | — | — | — | — | $130,000 |
| R&D expense | $18.13M | $15.74M | $16.97M | $14.17M | $11.00M |
| SG&A expense | $9.43M | $8.93M | $10.00M | $7.07M | $2.32M |
| Operating income | -$27.56M | -$24.68M | -$26.96M | -$21.24M | -$13.32M |
| Pretax income | -$26.61M | -$23.49M | — | — | — |
| Income tax | — | $2,000 | — | — | — |
| Net income | -$26.61M | -$23.49M | -$25.65M | -$13.89M | -$12.77M |
| EBITDA | -$27.13M | -$24.28M | -$26.61M | -$20.86M | -$12.98M |
| EPS (basic) | -0.43 | -0.43 | -0.50 | — | -0.27 |
| EPS (diluted) | -0.43 | -0.43 | -0.50 | — | -0.27 |
| Weighted avg. shares (diluted) | 62.39M | 54.98M | 50,853 | — | 32.82M |
| Balance sheet | |||||
| Cash & equivalents | $16.23M | $18.35M | $20.65M | $46.44M | $2.18M |
| Current assets | $17.90M | $20.44M | $23.06M | $47.53M | $2.47M |
| PP&E, net | $2.88M | $1.69M | $1.73M | $1.18M | $1.17M |
| Total assets | $39.39M | $41.56M | $45.80M | $51.13M | $5.45M |
| Current liabilities | $6.60M | $5.99M | $5.72M | $6.82M | $2.09M |
| Total liabilities | $23.66M | $23.95M | $25.04M | $6.82M | $2.99M |
| Shareholders' equity | $15.73M | $17.61M | $20.76M | $44.31M | $2.46M |
| Shares outstanding | 76.43M | 59.23M | 51.03M | 50,736 | 36.80M |
| Cash flow statement | |||||
| Operating cash flow | -$24.32M | -$20.79M | -$23.70M | -$18.79M | -$10.95M |
| Capital expenditure | $1.17M | $556,000 | $887,000 | $338,000 | $572,000 |
| Free cash flow | -$25.49M | -$21.34M | -$24.59M | -$19.12M | -$11.52M |
| Investing cash flow | -$1.17M | -$556,000 | -$887,000 | -$338,000 | -$572,000 |
| Financing cash flow | $23.27M | $19.05M | $133,000 | $63.39M | $11.62M |
| Depreciation & amortization | $424,000 | $400,000 | $357,000 | $381,000 | $345,000 |
| Stock-based compensation | $1.48M | $1.61M | $1.86M | $1.30M | $1.67M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.